These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2813190)

  • 21. [Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma].
    Li GZ; Zeng L; Zhang J; Yuan YM; Yang XY; Wang JH; Na YQ; Guo YL
    Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):493-5. PubMed ID: 14575578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
    Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
    Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue.
    Nakada SY; di Sant'Agnese PA; Moynes RA; Hiipakka RA; Liao S; Cockett AT; Abrahamsson PA
    Cancer Res; 1993 May; 53(9):1967-70. PubMed ID: 8481896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.
    Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H
    J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.
    Bonkhoff H; Stein U; Remberger K
    Hum Pathol; 1995 Feb; 26(2):167-70. PubMed ID: 7532147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
    Yu DS; Hsieh DS; Chen HI; Chang SY
    J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
    Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
    Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate.
    Abrahamsson PA; Wadström LB; Alumets J; Falkmer S; Grimelius L
    Pathol Res Pract; 1987 Jun; 182(3):298-307. PubMed ID: 2442732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
    Cox ME; Deeble PD; Lakhani S; Parsons SJ
    Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma.
    Abrahamsson PA; Cockett AT; di Sant'Agnese PA
    Prostate Suppl; 1998; 8():37-42. PubMed ID: 9690662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine differentiation in follicle-cell thyroid carcinoma: correlation to prognostic factors in papillary carcinoma.
    Tseleni-Balafouta S; Kavantzas N; Alevizaki M; Paraskevakou H; Davaris P
    J Exp Clin Cancer Res; 1998 Dec; 17(4):533-7. PubMed ID: 10089080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies.
    Casella R; Bubendorf L; Sauter G; Moch H; Mihatsch MJ; Gasser TC
    J Urol; 1998 Aug; 160(2):406-10. PubMed ID: 9679888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroendocrine differentiation in prostate cancer.
    Shariff AH; Ather MH
    Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
    [No Abstract]   [Full Text] [Related]  

  • 34. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
    Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
    Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroendocrine cells of the verumontanum: a comparative immunohistochemical study.
    Guy L; Bégin LR; Al-Othman K; Chevalier S; Aprikian AG
    Br J Urol; 1998 Nov; 82(5):738-43. PubMed ID: 9839592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromogranin A gene expression in non-small cell lung carcinomas.
    Abbona G; Papotti M; Viberti L; Macrĭ L; Stella A; Bussolati G
    J Pathol; 1998 Oct; 186(2):151-6. PubMed ID: 9924430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prostatic neuroendocrine cells].
    Herrero M; Rodríguez A; Cejas H
    Rev Fac Cien Med Univ Nac Cordoba; 2002; 59(1):91-6. PubMed ID: 12934249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroendocrine differentiation in colorectal carcinomas.
    Syversen U; Halvorsen T; Mårvik R; Waldum HL
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):667-74. PubMed ID: 8590163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine differentiation in human prostatic tumor models.
    Noordzij MA; van Weerden WM; de Ridder CM; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Am J Pathol; 1996 Sep; 149(3):859-71. PubMed ID: 8780390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroendocrine carcinomas of the breast.
    Rovera F; Masciocchi P; Coglitore A; La Rosa S; Dionigi G; Marelli M; Boni L; Dionigi R
    Int J Surg; 2008; 6 Suppl 1():S113-5. PubMed ID: 19167937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.